UbiQ Innovations is a spin-off company of the Netherlands Cancer Institute (NKI-AVL) founded in 2010. The company focuses on the ubiquitin system, a key cellular process involved in protein degradation and signaling that is implicated in numerous human diseases, including cancer and neurodegenerative disorders. UbiQ Innovations develops and commercializes high-quality reagents, assays, and provides high-throughput screening services to support academic and pharmaceutical research, with the ultimate mission of facilitating the development of new medicines targeting the ubiquitin system.

Founded in

Lebanon